Adamas Pharmaceuticals NASDAQ:ADMS is reporting this earnings, what to expect.
Adamas Pharmaceuticals NASDAQ:ADMS headquartered in Emeryville, California, United States is reporting their earnings on 05/02/2018 before the bell. Street forecast for the quarter ending March 2018 is $-1.38.
According to stock market daily analyst this is Lower then same time previous year. Adamas Pharmaceuticals reported EPS for the same quarter last year was $-0.72.
Overview of Adamas Pharmaceuticals NASDAQ:ADMS
Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company’s approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer’s disease. The company’s product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson’s disease, tardive dyskinesia, Huntington’s chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals was founded in 2000 and is headquartered in Emeryville, California.
|% Change from 52 Week Low|
|% Change from 52 Week High|